BIIB
BIOGEN INC.
Nasdaq: BIIB · Cambridge, MA · Healthcare
$250.69-3.15 (-1.24%)Closed
Market Cap$36.80B
Cash$2.91Bmost recent
Runwayprofitable
P/E (TTM)28.5EPS $8.79
52-Wk Range$147.86 – $253.84
Avg Volume1.4M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$250.69+36.3%
Pipeline

Drug candidates sponsored by BIOGEN · ClinicalTrials.gov

66 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Interferon-beta-1a
Relapsing-Remitting Multiple Sclerosis
Completed
2006-08past
1
Phase 4dimethyl fumarate
Multiple Sclerosis+4 more
Completed
2022-10-31past
9
Phase 4natalizumab
Relapsing Multiple Sclerosis+5 more
Completed
2024-04-30past
7
Phase 4Interferon beta-1a (Avonex)
Multiple Sclerosis
Completed—1
Phase 3BG9418 (interferon beta 1-a)
Multiple Sclerosis
Terminated
2009-02past
1
Phase 3tonapofylline
Renal Insufficiency+1 more
Completed
2009-10-30past
1
Phase 3Galiximab in combination with rituximab
Lymphoma, Non-Hodgkin's
Terminated
2010-01past
1
Phase 3BG00012
Relapsing-Remitting Multiple Sclerosis+2 more
Completed
2011-02past
3
Phase 3BG00002 (natalizumab)
Relapsing Remitting Multiple Sclerosis+1 more
Terminated
2012-04past
2
Phase 3BIIB019 (Daclizumab High Yield Process)
Relapsing-Remitting Multiple Sclerosis
Completed
2014-03past
1
Phase 3Daclizumab
Relapsing-Remitting Multiple Sclerosis (RRMS)
Terminated
2018-09-12past
1
Phase 3ALKS 8700
Relapsing Remitting Multiple Sclerosis
Completed
2019-06-27past
1
Phase 3BIIB111
Choroideremia
Completed
2020-12-01past
1
Phase 3SAGE-217
Depressive Disorder, Major+2 more
Completed
2022-03-15past
3
Phase 3Bardoxolone methyl oral capsule
Autosomal Dominant Polycystic Kidney+2 more
Completed
2023-08-08past
2
Phase 3nusinersen
Spinal Muscular Atrophy
Completed
2023-08-21past
3
Phase 3Aducanumab
Alzheimer's Disease
Terminated
2024-08-12past
1
Phase 3Litifilimab
Lupus Erythematosus, Systemic
Active, not recruiting
2026-09-30past
1
Phase 3BIIB017 (peginterferon beta-1a)
Multiple Sclerosis, Relapsing-Remitting
Active, not recruiting
2027-05-20
1
Phase 3Felzartamab
Immunoglobulin A Nephropathy (IgAN)
Recruiting
2027-05-31
1
Phase 3Tofersen
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation+1 more
Active, not recruiting
2027-08-07
2
Phase 3Salanersen
Muscular Atrophy, Spinal
Recruiting
2028-11-28
1
Phase 3Diroximel fumarate
Relapsing Forms of Multiple Sclerosis+2 more
Active, not recruiting
2031-01-17
3
Phase 3Alefacept
Chronic Plaque Psoriasis
Completed—1
Phase 2Interferon Beta-1a
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Completed
2006-02past
1
Phase 2BIIB014
Parkinson's Disease+1 more
Completed
2008-12past
2
Phase 2berubicin hydrochloride (RTA 744)
Brain Metastases
Terminated
2008-12-01past
1
Phase 2RTA 402 (Bardoxolone Methyl)
Diabetic Nephropathy
Completed
2009-05-31past
1
Phase 2BG9418 (Interferon beta-1a)
Active Ulcerative Colitis
Completed
2010-03past
1
Phase 2Lumiliximab + FCR
Chronic Lymphocytic Leukemia
Terminated
2010-06past
1
Phase 2Bardoxolone Methyl
Renal Insufficiency, Chronic+3 more
Completed
2012-11-30past
4
Phase 2CNV1014802
Lumbosacral Radiculopathy+1 more
Completed
2015-04-20past
2
Phase 2BIIB023
Lupus Nephritis
Terminated
2016-01past
1
Phase 2BIIB033
Multiple Sclerosis+2 more
Completed
2016-09past
3
Phase 2BIIB074
Primary Inherited Erythromelalgia
Completed
2016-12-27past
1
Phase 2BG00011
Idiopathic Pulmonary Fibrosis (IPF)
Completed
2017-03-31past
1
Phase 2Omaveloxolone Capsules, 2.5 mg
Friedreich Ataxia
Completed
2019-10-31past
1
Phase 2RTA 901
Diabetic Peripheral Neuropathic Pain
Terminated
2024-11-15past
1
Phase 2Diranersen
Mild Cognitive Impairment Due to Alzheimer's Disease+1 more
Active, not recruiting
2026-03-11past
1
Phase 1BIIB147
Amyotrophic Lateral Sclerosis
Recruiting
2034-01-23
1
Phase 2active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.
Parkinson's Disease
Withdrawn—1
Phase 1Unnamed
Healthy
Terminated
2011-04past
1
Phase 1Experimental
Healthy Volunteers
Completed
2011-09past
1
Phase 1BIIB028
Advanced Solid Tumors
Completed
2011-10past
1
Phase 1BIIB023 - low dose IV Dose
Healthy Volunteers
Completed
2012-02past
1
Phase 1PF-04958242 capsule
Healthy
Completed
2012-09past
1
Phase 1Placebo
Bipolar Depression+2 more
Completed
2012-12-14past
2
Phase 1BIIB037
Alzheimer's Disease
Completed
2013-08past
1
Phase 1BMS-986168
Tauopathies
Completed
2016-04-30past
1
Phase 1BIIB059 (litifilimab)
Systemic Lupus Erythematosus+1 more
Completed
2016-05-24past
1
Phase 1BIIB063
Healthy
Terminated
2016-06-01past
1
Phase 1BIIB092
Progressive Supranuclear Palsy
Completed
2016-10-19past
1
Phase 1BIIB033 (opicinumab)
Multiple Sclerosis+1 more
Completed
2016-11past
1
Phase 1SAGE-217 high dose
Healthy
Completed
2017-12-04past
1
Phase 1BIIB142
Healthy Volunteer
Recruiting
2026-08-06past
1
Phase 1Interferon-beta
Glioblastoma Multiforme+3 more
Completed—1
Early Phase 1Unnamed
Angelman Syndrome+1 more
Completed
2022-01-02past
1
N/AUnnamed
Relapsing-Remitting Multiple Sclerosis
Completed
2007-10past
1
N/AUnnamed
Multiple Sclerosis
Completed
2008-12past
1
N/ABG0002 (natalizumab)
Relapsing-Remitting Multiple Sclerosis
Completed
2011-03past
1
N/AUnnamed
Multiple Sclerosis
Completed
2014-11past
1
N/AUnnamed
Healthy+2 more
Completed
2017-08-22past
1
N/AUnnamed
Amyotrophic Lateral Sclerosis
Completed
2018-07-27past
1
N/AUnnamed
Multiple Sclerosis (MS)
Completed
2021-10-08past
1
N/AUnnamed
Multiple Sclerosis
Completed
2022-07-26past
1
N/ANusinersen Sodium Injection
Muscular Atrophy, Spinal
Active, not recruiting
2027-02-05
2
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.